JNJ vs DGX
By Alex · Tickerpine
Johnson & Johnson vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | DGX |
|---|---|---|
| Price | $285.75 | $259.60 |
| Market cap | $687.89B | $28.56B |
| P/E ratio | 43.4 | 25.9 |
| ROE | 20.02% | 15.32% |
| Profit margin | 16.20% | 9.54% |
| Revenue growth | 5.90% | 10.00% |
| Dividend yield | 1.88% | 1.33% |
| Beta | 0.20 | 0.55 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs DGX in plain English
- JNJ is the bigger company — about 24.1× the market cap of DGX.
- DGX is cheaper on earnings (P/E 25.9 vs 43.4).
- JNJ earns a higher return on equity (20% vs 15%).
- DGX is growing revenue faster (10% vs 6%).
- JNJ has the higher dividend yield (1.88% vs 1.33%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.